There is one clinical trial.
The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity
of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in
which one or more residents or staff have laboratory-confirmed COVID-19
Primary Outcomes
Measure: The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die Time: Through Week 4
Secondary Outcomes
Measure: The percentage of subjects who develop symptomatic laboratory-confirmed COVID-19 infection Time: Through Week 4
Measure: Mortality rate in subjects who develop laboratory-confirmed COVID19 Time: Through Week 8
Measure: Percent of subjects who are hospitalized due to having one or more predefined COVID-19 symptoms and laboratory-confirmed SARS-CoV-2 Time: Through Week 4
Measure: Percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or ICU admission during the hospitalization for COVID19 Time: Through Week 8
Measure: Safety and tolerability will be assessed by report of AE/SAEs Time: Through Week 5 and 8